Premium
Novel adopted immunotherapy for mixed chimerism after unrelated cord blood transplantation in Omenn syndrome
Author(s) -
Tomizawa Daisuke,
Aoki Yuki,
Nagasawa Masayuki,
Morio Tomohiro,
Kajiwara Michiko,
Sekine Teruaki,
Shimizu Norio,
Kato Masahiko,
Yachie Akihiro,
Mizutani Shuki
Publication year - 2005
Publication title -
european journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.904
H-Index - 84
eISSN - 1600-0609
pISSN - 0902-4441
DOI - 10.1111/j.1600-0609.2005.00535.x
Subject(s) - medicine , cord blood , immunosuppression , immunology , transplantation , severe combined immunodeficiency , immunodeficiency , umbilical cord blood transplantation , hematopoietic stem cell transplantation , surgery , immune system , in vivo , biology , microbiology and biotechnology
Omenn syndrome is a variant form of severe combined immunodeficiency. It is fatal unless treated by allogeneic stem cell transplantation (SCT), which is the only curative approach. However, both treatment‐related complications and graft rejection are major obstacles to treatment success. This report describes a case with Omenn syndrome who developed mixed chimerism after unrelated cord blood transplantation (UCBT). This case was successfully treated by altering the patient's immunosuppression and donor lymphocyte infusion (DLI) with donor cord blood‐derived activated CD4+ T cells ex vivo expanded from the cord blood cell residues in an infused bag. This novel development to expand CD4+ T‐lymphocytes from the donor cord blood unit for the use of DLI would serve as a useful method to overcome the risk of graft rejection in SCT for primary immunodeficiency disorders with residual cell‐mediated immunity without compounding graft‐vs.‐host disease, especially in the UCBT setting.